Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) COO Thomas W. Beetham purchased 5,000 shares of the firm's stock in a transaction on Friday, September 27th. The stock was bought at an average price of $23.41 per share, with a total value of $117,050.00. Following the acquisition, the chief operating officer now owns 6,000 shares in the company, valued at $140,460. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Viridian Therapeutics Stock Performance
VRDN stock opened at $22.75 on Tuesday. The stock's 50 day simple moving average is $17.15 and its 200 day simple moving average is $15.24. Viridian Therapeutics, Inc. has a 12-month low of $10.93 and a 12-month high of $24.18. The firm has a market cap of $1.45 billion, a P/E ratio of -5.06 and a beta of 1.03. The company has a current ratio of 15.82, a quick ratio of 15.82 and a debt-to-equity ratio of 0.05.
Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($1.02) earnings per share for the quarter, missing analysts' consensus estimates of ($0.87) by ($0.15). Viridian Therapeutics had a negative return on equity of 83.18% and a negative net margin of 79,185.77%. The business had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.09 million. As a group, equities research analysts predict that Viridian Therapeutics, Inc. will post -3.94 EPS for the current year.
Analyst Upgrades and Downgrades
Election rigged? We caught them red-handed…
From Banyan Hill Publishing | Ad
What happens if NOBODY will be elected the next President of the United States on Nov. 5?
Not Donald Trump. And not Kamala Harris.
The end result could be a 50% drop in the stock market.
You need to be ready.
Go here now for a FREE video about this surprising election forecast.
VRDN has been the subject of several analyst reports. BTIG Research upped their target price on shares of Viridian Therapeutics from $56.00 to $61.00 and gave the company a "buy" rating in a research note on Thursday, September 26th. Wolfe Research started coverage on shares of Viridian Therapeutics in a research report on Tuesday, June 11th. They issued an "outperform" rating and a $29.00 price objective for the company. Royal Bank of Canada reaffirmed an "outperform" rating and set a $44.00 target price on shares of Viridian Therapeutics in a research report on Thursday, September 19th. The Goldman Sachs Group increased their price target on Viridian Therapeutics from $25.00 to $31.00 and gave the company a "buy" rating in a report on Thursday, September 12th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $27.00 target price on shares of Viridian Therapeutics in a research report on Tuesday, September 10th. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $35.80.
View Our Latest Report on VRDN
Hedge Funds Weigh In On Viridian Therapeutics
A number of hedge funds and other institutional investors have recently bought and sold shares of VRDN. Quest Partners LLC raised its position in shares of Viridian Therapeutics by 344.0% during the 2nd quarter. Quest Partners LLC now owns 6,056 shares of the company's stock worth $79,000 after purchasing an additional 4,692 shares during the period. Ameritas Investment Partners Inc. increased its position in Viridian Therapeutics by 19.2% in the first quarter. Ameritas Investment Partners Inc. now owns 4,961 shares of the company's stock worth $87,000 after buying an additional 799 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Viridian Therapeutics by 24.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,961 shares of the company's stock valued at $156,000 after buying an additional 2,359 shares during the last quarter. AlphaCentric Advisors LLC boosted its holdings in shares of Viridian Therapeutics by 108.3% during the second quarter. AlphaCentric Advisors LLC now owns 12,500 shares of the company's stock valued at $163,000 after acquiring an additional 6,500 shares during the period. Finally, Arizona State Retirement System boosted its holdings in shares of Viridian Therapeutics by 14.7% during the second quarter. Arizona State Retirement System now owns 13,178 shares of the company's stock valued at $171,000 after acquiring an additional 1,688 shares during the period.
About Viridian Therapeutics
(
Get Free Report)
Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
